» Articles » PMID: 34789766

SPME-LC/MS-based Serum Metabolomic Phenotyping for Distinguishing Ovarian Cancer Histologic Subtypes: a Pilot Study

Overview
Journal Sci Rep
Specialty Science
Date 2021 Nov 18
PMID 34789766
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial ovarian cancer (EOC) is the most common cause of death from gynecological cancer. The outcomes of EOC are complicated, as it is often diagnosed late and comprises several heterogenous subtypes. As such, upfront treatment can be highly challenging. Although many significant advances in EOC management have been made over the past several decades, further work must be done to develop early detection tools capable of distinguishing between the various EOC subtypes. In this paper, we present a sophisticated analytical pipeline based on solid-phase microextraction (SPME) and three orthogonal LC/MS acquisition modes that facilitates the comprehensive mapping of a wide range of analytes in serum samples from patients with EOC. PLS-DA multivariate analysis of the metabolomic data was able to provide clear discrimination between all four main EOC subtypes: serous, endometrioid, clear cell, and mucinous carcinomas. The prognostic performance of discriminative metabolites and lipids was confirmed via multivariate receiver operating characteristic (ROC) analysis (AUC value > 88% with 20 features). Further pathway analysis using the top 57 dysregulated metabolic features showed distinct differences in amino acid, lipid, and steroids metabolism among the four EOC subtypes. Thus, metabolomic profiling can serve as a powerful tool for complementing histology in classifying EOC subtypes.

Citing Articles

Clinically relevant body composition phenotypes are associated with distinct circulating cytokine and metabolomic milieus in epithelial ovarian cancer patients.

Davis E, Hsiao H, Barone N, Rosario S, Cannioto R Front Immunol. 2024; 15:1419257.

PMID: 39575261 PMC: 11578747. DOI: 10.3389/fimmu.2024.1419257.


Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring.

Wang W, Zhen S, Ping Y, Wang L, Zhang Y Front Oncol. 2024; 14:1331215.

PMID: 38384814 PMC: 10879439. DOI: 10.3389/fonc.2024.1331215.


RETRACTED: Modern Subtype Classification and Outlier Detection Using the Attention Embedder to Transform Ovarian Cancer Diagnosis.

Nobel S, Swapno S, Hossain M, Safran M, Alfarhood S, Kabir M Tomography. 2024; 10(1):105-132.

PMID: 38250956 PMC: 11154515. DOI: 10.3390/tomography10010010.


Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy.

Lin Y, Zhou X, Ni Y, Zhao X, Liang X Front Immunol. 2022; 13:1030831.

PMID: 36311734 PMC: 9613923. DOI: 10.3389/fimmu.2022.1030831.


The metabolic fate of oxaliplatin in the biological milieu investigated during lung perfusion using a unique miniaturized sampling approach based on solid-phase microextraction coupled with liquid chromatography-mass spectrometry.

Olkowicz M, Rosales-Solano H, Ramadan K, Wang A, Cypel M, Pawliszyn J Front Cell Dev Biol. 2022; 10:928152.

PMID: 36092704 PMC: 9453651. DOI: 10.3389/fcell.2022.928152.

References
1.
Kulkarni J, Mistry R, Kamat M, Chinoy R, Lotlikar R . Autonomous aldosterone-secreting ovarian tumor. Gynecol Oncol. 1990; 37(2):284-9. DOI: 10.1016/0090-8258(90)90349-p. View

2.
Opitz C, Somarribas Patterson L, Mohapatra S, Dewi D, Sadik A, Platten M . The therapeutic potential of targeting tryptophan catabolism in cancer. Br J Cancer. 2019; 122(1):30-44. PMC: 6964670. DOI: 10.1038/s41416-019-0664-6. View

3.
Matulonis U, Sood A, Fallowfield L, Howitt B, Sehouli J, Karlan B . Ovarian cancer. Nat Rev Dis Primers. 2016; 2:16061. PMC: 7290868. DOI: 10.1038/nrdp.2016.61. View

4.
Looby N, Vasiljevic T, Reyes-Garces N, Roszkowska A, Bojko B, Wasowicz M . Therapeutic drug monitoring of tranexamic acid in plasma and urine of renally impaired patients using solid phase microextraction. Talanta. 2021; 225:121945. DOI: 10.1016/j.talanta.2020.121945. View

5.
Hu Y, Wang Z, Liu L, Zhu J, Zhang D, Xu M . Mass spectrometry-based chemical mapping and profiling toward molecular understanding of diseases in precision medicine. Chem Sci. 2021; 12(23):7993-8009. PMC: 8230026. DOI: 10.1039/d1sc00271f. View